Rawatan Immunotherapy Bagi Yang Memerlukannya

Kami merupakan sekumpulan pakar kajian yang menjalankan rawatan Cancer dengan menggunakan kadar Natural Immunotherapy.

Dari 198 kes Cancer yang datang kepada kami dari serata Malaysia dan Singapura, setakat ini kami telah hanya kehilangan 2 pesakit kerana Cancer ditubuh mereka telah merebak dengan dashyat sekali dan hanya tinggal beberapa hari lagi utuk mereka.

Alhamdulillah 196 kes lagi semua, Cancer mereka telah dapat diatasi.

Dengan kadar rawatan Natural Immunotherapy, anda tidak perlu menjalani Chemotherapy, Radiotherapy ataupun pembedahan.

Kebanyakkan Kes Cancer dapat diatasi dalam 3 bulan sahaja, Cancer yang paling mudah dirawati adalah Brain Tumor dikalangan kanak kanak (MedullaBlastoma) dan suksesnya adalah 100%. Leukemia mengambil masa yang agak lama sedikit, namun inshallah, boleh diatasi juga.

Kami tidak mengenakan sebarang bayaran, hanya kos barangan Immunotherapy sahaja yang sebenarnya amat berkemampuan oleh segala lapisan masyarakat jika dibandingkan dengan rawatan Konventional bagi Cancer.

Tujuan kami, adalah untuk memberi pertolongan dan kesan yang amat mujarab bagi setiap orang yang menderita Sakit Cancer. Bagi yang memerlukan bantuan atau mengenali sesiapa yang mungkin ada sakit Cancer, boleh menghubungi saya.

Ini bukan Iklan tetapi sebahgian dari usaha kami untuk menyelamatkan seberapa pesakit Cancer yang boleh. Walaupun beberapa hospital Swasta telah mengadu mereka telah kerugian besar kerana pesakit mereka telah menolak rawatan Chemo, namun kaedah kami tidak salah dari segi mana mana pihak dan kami berhak membantu mereka yang sedang menderita.

Sekian

Wasalam

speed2king

Camner nak proceed untuk consultation?

Contact me thru my e-mail aleem4life@gmail.com

Saya akan berada di Malaysia, Kuala Lumpur hanya untuk sehari sahaja, then I am flying off again. Jika mempunyai saudara mara atau sahabat handai yang mempunyai Kanser dan memerlukan pertolongan, insyallah saya akan cuba membantu. Semoga cepat sembuh.

Cuma saya tak akan ke hospital, sebab dua hospital swasta di KL tak akan benarkan saya masuk kerana ramai patient mereka sudah lari keluar dari sana dan telah pulih secara Immunotherapy. Wont mention the names though.

Wasalam

rebas

wow Chippo... you are saying that your immunotheraphy can cure brain tumour...great!! pls show me some clinical trials.. (evidence based)
before i  send you all my brain tumour patients out to your immunotheraphy ...
you havent mail me your hard copies... remember?the hard copies on transfer factor? i tak dapat lagi oo..


right here waiting...
...rebas001@yahoo.co.uk

hasaru

saya pasti dr rebas pasti happy kalau pesakit brain tumour dia sembuh....apa kaedahpun yg dipakai utk menyembuh....

kita hanya berusaha........

blackmore

Originally posted by hasaru at 17-7-2006 06:47 PM
saya pasti dr rebas pasti happy kalau pesakit brain tumour dia sembuh....apa kaedahpun yg dipakai utk menyembuh....

kita hanya berusaha........

...yes rite...aku pon turut happy...tapi...in the attempt to promote or make aware of  immunotherapy...janganlah pulak nak condemn other forms of treatments as being useless and endangering the lives of the cancer patients......surgery has always been the mainstay of treatment for most cancers...chemotherapy...radiation therapy nie semua has proven to be able to cure and treat cancer also...

...all im asking is to be fair in your opinions and judgement...takmolah bias sangat...atau taksub sangat ngan satu2 kaedah rawatan...:tq:

rebas

Originally posted by hasaru at 17-7-2006 06:47 PM
saya pasti dr rebas pasti happy kalau pesakit brain tumour dia sembuh....apa kaedahpun yg dipakai utk menyembuh....

kita hanya berusaha........

well.. kita kat gomen hospital will be more than happy kalau pesakit2 ni baik..
tapi nak apply sesuatu treatment tu.. tak boleh pakai ikut sesuka hati.. kena ada evidence barulah govt akan beli this ubat untuk kegunaan pesakit..

unfortunately.. so far tak de evidence yg kukuh.. anybody boleh claim ubatnya berkesan.. tapi without evidence.. no hospital/ govt akan pakai..
.... worse still geram jugak aku bila terima pesakit yg defaulted treatment sbb makan ubat traditional tu dalam keadaan koma.. too late..and  too bad..

Originally posted by rebas at 17-7-2006 07:00 PM



well.. kita kat gomen hospital will be more than happy kalau pesakit2 ni baik..
tapi nak apply sesuatu treatment tu.. tak boleh pakai ikut sesuka hati.. kena ada evidence barulah govt akan b ...

:setuju: sebab dah banyak bukti yg apply rx traditional came with worse complication..........so up to the patient to decide

Originally posted by rebas at 17-7-2006 06:21 PM
wow Chippo... you are saying that your immunotheraphy can cure brain tumour...great!! pls show me some clinical trials.. (evidence based)
before i  send you all my brain tumour patients out to you ...

Hi Rebas,

Sorry if I have stirred up your emotions again in respect of the treatment that we are offering. By the way when I say hard copies, I mean hard copies and not soft copies, so how would u expect me to e-mail u hard copies.

Well anyway, since I am not always in Malaysia, why dont I give u the contact number of a Dr and perhaps you give him a call and find out whatever you need to know about this. Probably he can meet you some place and extend all the documents that you require.

By the way this Dr always gets referral from the Head Oncologist in a few hospitals in KL dimana pihak hospital kata dah takda harapan lagi. He will also show you actual cases of patients yang dah recover, kebanyakkan kanak kanak di Malaysia.

And for everyone's information, kadar rawatan ini bukan rawatan traditional. It is based on 57 years of scientific research and over US40 Million dollars in research.

I will PM you his contact number.

Cheers and take care

Wasalam

Originally posted by rebas at 17-7-2006 07:00 PM



well.. kita kat gomen hospital will be more than happy kalau pesakit2 ni baik..
tapi nak apply sesuatu treatment tu.. tak boleh pakai ikut sesuka hati.. kena ada evidence barulah govt akan b ...

If I may, please allow me to re-phrase that again. Bukan takda hospital dan Govt yang tak pakai, infact seluruh Hospital di Russia pakai cara ini. I even have a book by the Ministry of Social Development and Health of the Russian Federation of States yang ada keluarkan table, jika terjadi HIV, berapa Dosage nak pakai, Jika Cancer berapa Dosage nak Pakai dan Jika Hepatitis berapa Dosage nak pakai.

Kementrian Kesihatan Russia yang teknologinya jauh lebih tinggi dari kita tak akan keluarkan buku panduan tanpa usul periksa terlebih dahulu dan tak akan dengan serbarangan membuat pengakuan bahawa cara ini setakat ini paling berkesan dalam bidang perubatan.

Then bagaimana pula dengan naskah majalah TOTAL HEALTH yang ditulis oleh 6 orang doktor Pakar di USA dimana circulationya adalah 60,000 naskah sehari. Keluar pula dua muka surat tentang kajian TF dan bagaimana seluruh saintist sebulat suara bersetuju bahawa ini mungkin benteng pertahanan manusia terakhir jika terjadi penularan demam burung.

Surely you cannot tell me 6 orang pakar perubatan yang tiada kena mengena dengan syarikat kajian sains ini akan mengeluarkan artikle sebegini jika tiada kajian kukuh.  

I don't wanna start another debate here, I dah sertakan number talipon untuk u. My intention here is bringing a wave of good health in Malaysia supaya kita semua dijauhkan dari penyakit2 merbahaya dan sihat selalu.

Wasalam

rebas

ala.. cant you just mail me yr research, clinical trials.. for the sake of all... ask that dr Zainal to mail me.. i am hardly contactable daytime..i wanna see some evidence..why so difficult?



BTW.. some childhood brain tumours eg. neuroblastoma do not need treatment they are benign and resolve by itself ..

[ Last edited by  rebas at 18-7-2006 06:37 PM ]

Well if you are so interested to see the medical evidence, then you should make the effort to contact him. Like I said earlier, it does not matter whether you believe in this, its totally irrelevant becos we have an influx of doctors are specialists who are joining our family of good health. Sooner or later, you will bound to come to hear of this.

of course some brain tumors in kids are benign, no one is denying that, but the cases we had were all not benign tumors and had all gone thru diff prcedures in hospitals. I would not wish to carry on this debate, because it is not gonna make a difference to whether u believe in such treatments or not.

Seriously, if you are keen to know the facts, then do make an effort to find out yourself. I have given you the relevant contact numbers.

Cheers

Assalamualaikum,

Adik saya dulu mengidapi Cancer Buah Dada. Dia telah menjalani rawatan pembedahan dan Chemotherapy. Sebahgian dari buah dada dia telah dibuang. Selepas 3 bulan doktor mengesahkan Cancer buah dadanya telah merebak ke sebelah pula. Mujur waktu itu kami dipekenalkan dengan Dr Zainal, dia adalah kenalan ketua Oncologist di University Hospital.

Selepas 3 bulan dan hanya dengan rawatan Imun beliau, Cancer dibuah dada adik saya hilang sama sekali dan tidak perlu dibedah sama sekali. Doktor telah memberi jawapan yang sungguh memuaskan. Walau apapun pendapat pendapat doktor disini, saya tetap menyokong TF 100% kerana telah berjaya merawat adik saya yang telah tiada harapan lagi.

Clinical Trial yang ada berkenaan Transfer Factor dan cara pengunaannya. Terdapat lebih dari 3500 lagi CLinical Trial yang tidak dapat dipaparkan disini kerana saya tidak mempunyai soft copynya. Hanya dalam hard copy, yang dicetak semasa menghadiri Symposium TF Sedunia.

Transfer factor with anti-EBV activity as an adjuvant therapy for nasopharyngeal carcinoma: a pilot study.
Biotherapy 1996;9(1-3):109-15
Transfer factor with anti-EBV activitiesy a

Prasad U, bin Jalaludin MA, Rajadurai P, Pizza G, De Vinci C, Viza D, Levine PH.
University of Malaya, Kuala Lumpur, Malaysia.

Overall survival of nasopharyngeal carcinoma (NPC) at UICC stage IV still remains unsatisfactory even with combination chemotherapy (CT) and radio-therapy (RT). In view of the association of reactivation of Epstein-Barr virus (EBV) with the development and recurrence of NPC, immunotherapy in the form of transfer factor (TF) with specific activity against EBV (TF-B1) was suggested as an adjuvant to a combination of CT and RT in order to improve survival.

In the present study, 6 UICC stage IV patients received TF-B1 and another 6 patients matched for disease stage were given TF prepared from peripheral blood leucocytes (TF-PBL).

Results were compared with another 18 patients matched by age, sex, and stage of disease who received standard therapy without TF during the same period (C group). After a median follow up of 47.5 months, the survival for the TF-B1 group was found to be significantly better (P = < 0.05) than the PBL and C group. While the 8 patients with distant metastasis (DM), not treated with TF-B1 (6 in the control and 2 in the PBL group), died due to progressive disease (average survival being 14.3 months), both patients with DM in the TF-B1 group had complete remission: one died of tuberculosis after surviving for 3.5 years and another is still alive, disease free, after 4.2 years.

Although the series involved a small number of cases, the apparent effect of adjuvant immunotherapy in the form of TF with anti-EBV activity is of considerable interest.

Publication Types: Clinical Trial
Controlled Clinical Trial
PMID: 8993768 [PubMed - indexed for MEDLINE]

Effect of transfer factor on myelosuppression and related morbidity induced by chemotherapy in acute leukaemias.
Br J Haematol 1993 Jul;84(3):423-7

Fernandez O, Diaz N, Morales E, Toledo J, Hernandez E, Rojas S, Madriz X, Lopez Saura P.
Hospital Universitario Dr. Carlos J. Finlay, Marianao, Cuba.

The aim of this study is to determine the safety and efficacy of Transfer Factor (TF) in accelerating the haematopoietic recovery in patients with acute leukaemias (AL), following intensive therapy to induce remission of the disease.

Twenty-two patients with different types of AL (16 AML, three BC-CML and three ALL) were studied. The patients were divided in two groups. Group 1 (eight AML, two BC-CML and one ALL) received, after myelosuppression induced by chemotherapy, TF (1 unit daily, subcutaneous) until leucocyte count was > 2.5 x 10(9)/l and platelet count > 80 x 10(9)/l. Group 2 was considered the control group and did not receive TF.

Treatment with TF accelerated the recovery of neutrophils, leucocytes, platelets (P < 0.001) and haemoglobin (P < 0.01). As a logical consequence, incidence and severity of infection and haemorrhage were lesser in the TF group than in the control group. There was no evidence that TF accelerated the re-growth of leukaemic cells. It seems that TF is safe in AL, accelerating haematopoietic recovery. However, it should be used with caution until results of additional trials become available.

Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 8217793 [PubMed - indexed for MEDLINE]

Preliminary observations using HIV-specific transfer factor in AIDS.
Biotherapy 1996;9(1-3):41-7


Pizza G, Chiodo F, Colangeli V, Gritti F, Raise E, Fudenberg HH, De Vinci C, Viza D.
Immunodiagnosis and Immunotherapy Unit, Ospedale S. Orsola-Malpighi, Bologna, Italy.

Twenty five HIV-1-infected patients, at various stages (CDC II, III and IV) were treated orally with HIV-1-specific transfer factor (TF) for periods varying from 60 to 1870 days. All patients were receiving antiviral treatments in association with TF.

The number of lymphocytes, CD4 and CD8 subsets were followed and showed no statistically significant variations. In 11/25 patients the number of lymphocytes increased, whilst in 11/25 decreased; similarly an increase of the CD4 lymphocytes was observed in 11/25 patients and of the CD8 lymphocytes in 15/25.

Clinical improvement or a stabilized clinical condition was noticed in 20/25 patients, whilst a deterioration was seen in 5/25. In 12/14 anergic patients, daily TF administration restored delayed type hypersensitivity to recall antigens within 60 days. These preliminary observations suggest that oral HIV-specific TF administration, in association with antiviral drugs, is well tolerated and seems beneficial to AIDS patients, thus warranting further investigation.

Publication Types:
Clinical Trial
Clinical Trial, Phase I
PMID: 8993756 [PubMed - indexed for MEDLINE]

Immunomodulatory therapy of epilepsy with transfer factor
Bratisl Lek Listy 1997 Apr;98(4):234-7
[Article in Slovak]

Simko M, Mokran V, Nyulassy S.
Zdruzene lekarsko-imunologicke pracovisko Ustavu preventivnej a klinickej mediciny a Dererovej Nemocnice a poliklinikou v Bratislave, Slovakia.

Effect of immunotherapy with Transfer factor administered for a period of three months was studied in a group of ten epileptic patients, treated with carbamazepine or primidon previously and throughout the study. Out of eight patients, who finished the study we could notice significant reduction of epileptic discharges in eight patients. The results of this study prove that addition of immunomodulatory treatment to patients with intractable epilepsy could substantially improve the course of the disease in some patients. (Tab. 1, Fig. 5, Ref. 13.)

Publication Types:
Clinical Trial
Controlled Clinical Trial
PMID: 9264833 [PubMed - indexed for MEDLINE]

Transference factor in moderate and severe atopic dermatitis
Rev Alerg Mex 1996 Sep-Oct;43(5):116-23
[Article in Spanish]

Navarro Cruz D, Serrano Miranda E, Orea M, Estrada Parra S, Teran Ortiz L, Gomez Vera J, Flores Sandoval G.
Servicio de alergologia e inmunologia clinica, Hospital Regional Lic, Adolfo Lopez Mateos, ISSSTE.

We did a prospective, comparative, experimental study with 30 patients with moderate to severe atopic dermatitis from the allergy section from September 1994 to March, 1995. The test laboratory examination was performed in all patients: complete blood cell count, immunoglobulins A, G, M and E determination, lymphocyte subpopulations CD3, CD4, CD8, CD4-CD8 proportion, CD25, rosette formation for B and T lymphocytes, coproparasitoscopic examination, throat and nose cultures, nasal cytology, skin tests of cellular immunity to PPD, thrichophytin, candidine, varidasa; skin prick test to poliens, fungi, inhalants and foods.

All patients underwent to a sign and symptom grading score system as follows: the parameters were erythema, pruritus, eczema, papule valorated on a scale from 0 a 4+( O = no symptoms, + = mild, ++ = moderate, + ++= severe, ++ ++ = very severe). Initially all patients received one placebo unit every 15 days orally 3 times, then one after 30 days.

Laboratory examination was performed and then treatment with transfer factor was initiated, initially 1 unit every 15 days three times and the fourth 30 days after. 15 days after the last dose a new immunological valoration was done.

Results demonstrate a CD4 cell decrement, blood eosinophil and lgE dissemination although they're not statistically significative. There was a statistically significative improvement in the 4 clinical parameters: erythema, eczema, pruritus and populous with the use of Transfer Factor.

PMID: 9005003 [PubMed - indexed for MEDLINE]

Safety and efficacy of treatment for severe atopic dermatitis with cyclosporin A and transfer factor
Rev Alerg Mex 1999 Mar-Apr;46(2):49-57
[Article in Spanish]

Cordero Miranda MA, Flores Sandoval G, Orea Solano M, Estrada Parra S, Serrano Miranda E.
Servicio de alergia e inmunologia, Hospital Regional Lic. Adolfo Lopez Mateos, ISSSTE.

BACKGROUND: The atopic dermatitis is a chronic skin disease that appears in patients with a personal or family history of allergic asthma and rhinitis. It is associated to the specific activation of a gene group. In most instances, the response to the conventional treatment is adequate. The are cases, though, know as refractory, where that is not the case. The study of two therapeutic alternatives, Transfer Factor (TF) and Cyclosporin A (CyA), was elaborated for this type of patients.

MATERIAL AND METHODS: Patients with severe refractory AD were studied, being admitted to the Allergic Service to the ISSSTE Lic. Adolfo Lopez Mateos, ISSSTE, between September 1997 and june 1998. They were randomly divided in two groups. The first one was subjected to CyA, on a 4 mg/kg/day dosage, with monthly surveillance of kidney and hepatic functions and blood pressure twice a week. Group two was subjected to TF, as follows: one unit every third day for the first week, two units per week for the next three weeks and one monthly unit to complete six months. Initial and final clinical and immunologic testing was performed on both groups (eosinophils, total IgE, CD4 and CD8).

RESULTS: Six patients included group A, and 12 patients in group B. Both groups showed a significant statistic reduction in the total eosinophils count, without an statistic difference between them. None showed changes in the total IgE. CyA reduced the CD4 levels, while the TF increased the levels of CD8 cells, both with a p < 0.05. Both groups showed clinical improvement satistically significant, but no differences with a p > 0.05 appeared between them. Tolerance to the treatments was adequate, and there was not need to suspend the treatment in any case. Only three patients showed hypertricosis and other one presented headaches, with CyA.

CONCLUSION: Both treatments showed therapeutic benefits in the treatment of patients with severe refractory AD, with similar immunologic improvement. Both drugs present different action mechanisms, so their joint application could offer clinical benefit to the patient (synergetic action), cost reduction, and long term treatments with reduced adverse effects.

Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 10391070 [PubMed - indexed for MEDLINE]

Use of transfer factor for the treatment of recurrent non-bacterial female cystitis (NBRC): a preliminary report.
Biotherapy 1996;9(1-3):133-8

De Vinci C, Pizza G, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Masi M, Severini G, Fornarola V, Viza D.
Immunodiagnosis and Immunotherapy Unit, 1st-Division of Urology, Bologna, Italy.

Results of conventional treatment of female non-bacterial recurrent cystitis (NBRC) are discouraging. Most patients show an unexpected high incidence of vaginal candidiasis, while their cell mediated immunity to Herpes simplex viruses (HSV) and Candida antigens seems impaired, and it is known that the persistence of mucocutaneous chronic candidiasis is mainly due to a selective defect of CMI to Candida antigens.
Twenty nine women suffering of NBRC, and in whom previous treatment with antibiotics and non-steroid anti-inflammatory drugs was unsuccessful, underwent oral transfer factor (TF) therapy. TF specific to Candida and/or to HSV was administered bi-weekly for the first 2 weeks, and then once a week for the following 6 months. No side effects were observed during treatment. The total observation period of our cohort was 24379 days with 353 episodes of cystitis recorded and a cumulative relapse index (RI) of 43.

The observation period during and after treatment was 13920 days with 108 relapses and a cumulative RI of 23 (P < 0.0001). It, thus, seems that specific TF may be capable of controlling NBRC and alleviate the symptoms.

Publication Types:
Clinical Trial
PMID: 8993771 [PubMed - indexed for MEDLINE

Transfer factor in chronic mucocutaneous candidiasis.
Biotherapy 1996;9(1-3):97-103

Masi M, De Vinci C, Baricordi OR.
Department of Pediatrics, University of Bologna, Italy.

Fifteen patients suffering from chronic mucocutaneous candidiasis were treated with an in vitro produced TF specific for Candida albicans antigens and/or with TF extracted from pooled buffy coats of blood donors. CMI of the patients was assessed using the LMT and the LST in presence of candidine.

The aim of the study was the clinical evaluation of TF treatment and the incidence of positive tests before, during, and after therapy. Immunological data were matched using the Chi square test. 87 LMT were performed for each antigen dose and at the dilution of 1/50, 58.9% (33/56) tests were positive during non-treatment or non-specific TF treatment. On the contrary 83.9% (26/31) were positive during specific TF treatment (P < 0.05). In the LST, a significant decrease of thymidine uptake in the control cultures in presence of autologous or AB serum was observed when patients were matched according to non-treatment, and both non specific (P < 0.05) and specific TF treatment (P < 0.01). Only during specific TF treatment was a significant increase of reactivity against the Candida antigen at the highest concentration noticed, when compared with the period of non specific treatment (P < 0.01).

Clinical observations were encouraging: all but one patient experienced significant improvement during treatment with specific TF. These data confirm that orally administered specific TF, extracted from induced lymphoblastoid cell-lines, increases the incidence of reactivity against Candida antigens in the LMT. LST reactivity appeared not significantly increased with respect to the periods of non treatment, but was significantly increased when it was compared to the non-specific TF treatment periods. At the same time, a clinical improvement was noticed.

Publication Types:
Clinical Trial
PMID: 8993766 [PubMed - indexed for MEDLINE]

Comparative study of transfer factor and acyclovir in the treatment of herpes zoster.
Int J Immunopharmacol 1998 Oct;20(10):521-35

Estrada-Parra S, Nagaya A, Serrano E, Rodriguez O, Santamaria V, Ondarza R, Chavez R, Correa B, Monges A, Cabezas R, Calva C, Estrada-Garcia I.
Department of Immunology, National School of Biological Sciences, National Polytechnic Institute, Prol. Carpio Y Plan de Ayala, Mexico, D.F. i-estrad@bios.encb.ipn.mx

Reactivation of varicella herpes virus (VHV), latent in individuals who have previously suffered varicella, gives rise to herpes zoster and in some cases leads to a sequela of post herpetic neuritis with severe pain which is refractory to analgesics. Many different antiviral agents have been tried without achieving satisfactory results. Of all the antiviral agents employed, acyclovir has been the most successful in reducing post herpetic pain. However acyclovir has not been as reliable as interferon alpha (IFN-alpha).

We have previously looked into the use of transfer factor (TF) as a modulator of the immune system, specifically with respect to its effectiveness in the treatment of herpes zoster. In this work findings from a comparative clinical evaluation are presented. A double blind clinical trial of TF vs acyclovir was carried out in which 28 patients, presenting acute stage herpes zoster, were randomly assigned to either treatment group.

Treatment was administered for seven days and the patients were subsequently submitted to daily clinical observation for an additional 14 days. An analogue visual scale was implemented in order to record pain and thereby served as the clinical parameter for scoring results. The group treated with TF was found to have a more favorable clinical course, P < or = 0.015. Laboratory tests to assess the immune profile of the patients were performed two days prior and 14 days after initial treatment. The results of these tests showed an increase in IFN-gamma levels, augmentation in the CD4+ cell population but not the percentage of T rosettes in the TF treated group. These parameters were however insignificantly modified in patients receiving acyclovir.

Although TF treated patients showed an increase in CD4+ counts these cells remained below the levels for healthy individuals. The fact that IFN-gamma levels as well as the counts for CD4+ cells rose in the TF treated group and not in the acyclovir one is very significant and confirms the immunomodulating properties of TF.

Publication Types:
Clinical Trial
Randomized Controlled Trial
PMID: 9839657 [PubMed - indexed for MEDLINE]

Orally administered HSV-specific transfer factor (TF) prevents genital or labial herpes relapses.
Biotherapy 1996;9(1-3):67-72

Pizza G, Viza D, De Vinci C, Palareti A, Cuzzocrea D, Fornarola V, Baricordi R.
Immunodiagnosis and Immunotherapy Unit, 1st-Division of Urology, S. Orsola-Malpighi Hospital, Bologna, Italy.

Forty-four patients suffering from genital (22) and labial (22) herpes were orally treated with HSV-1/2-specific transfer factor (TF). TF was obtained by in vitro replication of a HSV-1/2-specific bovine dialysable lymphocyte extract. Treatment was administered bi-weekly the first 2 weeks, and then weekly for 6 months, most patients received 2-3 courses. The total observation period for all patients before treatment was 26,660 days, with 544 relapses, and a relapse index of 61.2, whereas the cumulative observation period during and after treatment was 16,945 days, with a total of 121 relapsing episodes and a cumulative RI of 21.4 (P < 0.0001). Results were equally significant when the 2 groups of patients (labial and genital) were considered separately.

These observations confirm previous results obtained with bovine HSV-specific TF, and warrant further studies to establish HSV-specific TF as a choice of treatment for preventing herpes recurrences.

PMID: 8993760 [PubMed - indexed for MEDLINE]


Immunotherapy with transfer factor of recurrent herpes simplex type I.
Arch Med Res 1995;26 Spec No:S87-92

Estrada-Parra S, Chavez-Sanchez R, Ondarza-Aguilera R, Correa-Meza B, Serrano-Miranda E, Monges-Nicolau A, Calva-Pellicer C.
Departamento de Inmunologia, Escuela Nacional de Ciencias Biologicas, Instituto Politecnico Nacional, Mexico, D.F.

This clinical trial of Transfer Factor, an immunomodulator, in the treatment of herpes simplex type I, proved this agent to be more effective as regards duration of acute phase recurrences as well as the frequency of the reappearance of relapses of this disease.

The evaluation was made in 20 patients whose disease had been treated before with other therapeutic agents (including acyclovir) which permitted them to be their own controls for the comparative data obtained and submitted to statistical analysis of the two parameters mentioned, duration of the acute phase and frequency of relapses. Patients with compromised cellular immunity or with any additional disease were excluded from the study.

Transfer factor, one unit, was administered subcutaneously daily for 3 to 4 days during the acute phase of the disease, and subsequently at 15-day intervals for the first 6 months; followed by a continuation of monthly injections until the termination of the study period. In six of the 20 patients there was a recurrence of the disease while receiving maintenance dosages of TF. These patients were again given the full initial dosage schedule and reinstated again with the maintenance dosage. In the initial eight patients, an immune status profile was obtained, and all results were found to be in the normal range. This was considered sufficient evidence that the criteria for the selection of patients excluded any with detectable variations in the profile of the immune status, and it was decided to eliminate this as a prerequisite for participating in the study.

The results showed an important improvement in the response to transfer factor immune modulation therapy. A statistically significant reduction in the frequency of recurrences within a one month period, the Student t test gave a p = 0.0001 in TF treated patients. The average duration in days of the acute phase also showed an important difference in favor of the TF treatment. The U Mann-Whitney test gave a p = 0.0005. These results suggest that, at present, TF may be considered the therapeutic agent of choice in the treatment of herpes simplex type 1 disease.

Publication Types:
Clinical Trial
Controlled Clinical Trial
PMID: 8845664 [PubMed - indexed for MEDLINE]

Transfer factor prevents relapses in herpes keratitis patients: a pilot study.
Biotherapy 1994;8(1):63-8

Pizza G, Meduri R, De Vinci C, Scorolli L, Viza D.
Immunodiagnosis and Immunotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, Italy.

Transfer Factor is a dialysable moiety obtained from immune lymphocytes. It has been successfully used for the treatment of several viral infections including labial and genital herpes. In the present study, thirty-three patients with low immune response to HSV antigens and suffering from herpes ocular infections were orally treated with HSV-specific transfer factor (TF). Their relapse index was reduced from 20.1 before treatment to 0.51 after TF administration, with only 6/33 patients relapsing. Although this is not a placebo-controlled-randomized study, the results suggest that TF specific for HSV antigens may be efficacious for preventing relapses of ocular herpes infections as has been the case with genital and labial localisations.

Publication Types:
Clinical Trial
PMID: 7547082 [PubMed - indexed for MEDLINE]

The influence of age on transfer factor treatment of cellular immunodeficiency, chronic fatigue syndrome and/or chronic viral infections.
Biotherapy 1996;9(1-3):91-5

Hana I, Vrubel J, Pekarek J, Cech K.
Dept. of Immunology, Institute for Clinical and Experimental Medicine, Prague, Czechia.

A group of 222 patients suffering from cellular immunodeficiency (CID), frequently combined with chronic fatigue syndrome (CFS) and/or chronic viral infections by Epstein-Barr virus (EBV) and/or cytomegalovirus (CMV), were immunologically investigated and treated with transfer factor (TF). The age range was 17-77 years. In order to elucidate the influence of aging on the course of the disease and on treatment, 3 subgroups were formed: 17-43 years, 44-53 years, and 54-77 years. Six injections of Immodin (commercial preparation of TF by SEVAC, Prague) were given in the course of 8 weeks. When active viral infection was present, IgG injections and vitamins were added. Immunological investigation was performed before the start of therapy, and subsequently according to need, but not later than after 3 months.

The percentages of failures to improve clinical status of patients were in the individual subgroups, respectively: 10.6%, 11.5% and 28.9%. The influence of increasing age on the percentage of failures to normalize low numbers of T cells was very evident: 10.6%, 21.2% and 59.6%. In individuals uneffected by therapy, persistent absolute lymphocyte numbers below 1,200 cells were found in 23.1%, 54.5% and 89.3% in the oldest group.

Statistical analysis by Pearson's Chi-square test, and the test for linear trend proved that the differences among the individual age groups were significant. Neither sex, nor other factors seemed to influence the results.

The results of this pilot study show that age substantially influences the failure rate of CID treatment using TF. In older people, it is easier to improve the clinical condition than CID: this may be related to the diminished number of lymphocytes, however, a placebo effect cannot be totally excluded.

Publication Types:
Clinical Trial
PMID: 8993765 [PubMed - indexed for MEDLINE]

Increased tumor necrosis factor alpha (TNF-alpha) and natural killer cell (NK) function using an integrative approach in late stage cancers.
Immunol Invest 2002 May;31(2):137-53

See D, Mason S, Roshan R.
Center for Advanced Medicine, Encinitias, California 92024, USA. darrylsee@cs.com

Natural products may increase cytotoxic activity of Natural Killer Cells (NK) Tumor Necrosis Factor alpha (TNF-alpha) while decreasing DNA damage in patients with late-stage cancer. Pilot studies have suggested that a combination of Nutraceuticals can raise NK cell function and TNF-alpha alpha activity and result in improved clinical outcomes in patients with late stage cancer.

The objective of the study is to determine if Nutraceuticals can significantly raise NK function and TNF levels in patients with late stage cancer. After informed consent was obtained, 20 patients with stage IV, end-stage cancer were evaluated (one bladder, five breast, two prostate, one neuroblastoma, two non-small cell lung, three colon, 1 mesothelioma, two lymphoma, one ovarian, one gastric, one osteosarcoma).
Transfer Factor Plus (TFP+, 3 tablets 3 times per day), IMUPlus (non denatured milk whey protein, 40 gm/day); Intravenous (50 to 100 gm/day) and oral (1-2 gm/day) ascorbic acid; Agaricus Blazeii Murill teas (10 gm/day); Immune Modulator Mix (a combination of vitamin, minerals, antioxidants and immune-enhancing natural products); nitrogenated soy extract (high levels of genistein and dadzein) and Andrographis Paniculata (500 mg twice, daily) were used.
Baseline NK function by standard 4 h 51Cr release assay and TNF alpha and receptor levels were measured by ELISA from resting and phytohemagglutinin (PHA) stimulated adherent and non-adherent Peripheral Blood Mononuclear Cell (PBMC). Total mercaptans and glutathione in plasma were taken and compared to levels measured 6 months later. Complete blood counts and chemistry panels were routinely monitored.

As of a mean of 6 months, 16/20 patients were still alive. The 16 survivors had significantly higher NK function than baseline (p < .01 for each) and TNF-alpha levels in all four cell populations studied (p < .01 for each). Total mercaptans (p < .01) and TNF-alpha receptor levels were significantly reduced (p < .01). It was also observed that hemoglobin, hematocrit and glutathione levels were significantly elevated. The only toxicity noted was occasional diarrhea and nausea. The quality of life improved for all survivors by SF-36 form evaluation.
An aggressive combination of immunoactive Nutraceuticals was effective in significantly increasing NK function, other immune parameters and hemoglobin from PBMC or plasma in patients with late stage cancers. Nutraceutical combinations may be effective in late stage cancers. Clinical outcomes evaluations are ongoing.

PMID: 12148949 [PubMed - in process]

Adjuvant treatment using transfer factor for bronchogenic carcinoma: long-term follow-up.
Ann Thorac Surg 1992 Mar;53(3):391-6

Whyte RI, Schork MA, Sloan H, Orringer MB, Kirsh MM.
Section of Thoracic Surgery, University of Michigan, Ann Arbor.

Transfer factor, a dialyzable lymphocyte extract that may act as an immune stimulator by transferring antigen-specific immunity between genetically dissimilar individuals, was administered in a prospective, randomized study to patients with non-small cell bronchogenic carcinoma.

Between 1976 and 1982, 63 patients who underwent pulmonary resection, mediastinal lymph node dissection, and, when indicated by the presence of mediastinal lymph node involvement, mediastinal irradiation were randomized into two groups. Group 1 (n = 28) received 1 mL of pooled transfer factor at 3-month intervals after operation; group 2 (n = 35 ) served as controls and received saline solution.

There were no statistically significant differences between the two groups with respect to age, sex, tumor histology, stage of disease, or extent of resection. One patient was lost to follow-up at 96 months; follow-up was complete in all others through July 1990.

In patients receiving transfer factor, the 2-, 5-, and 10-year survival rates were 82%, 64%, and 43% respectively, whereas in controls they were 63%, 43%, and 23%. Survival in patients receiving transfer factor was consistently better than in those receiving placebo.

Furthermore, survival in patients receiving transfer factor was greater at all stages of disease for both adenocarcinoma and squamous cell carcinoma. Although these long-term results were not statistically significant using survival analysis with covariates (p = 0.08), they confirm our previously reported short-term findings suggesting that administration of transfer factor, either through nonspecific immune stimulation, enhancement of cell-mediated immunity, or an as yet undefined mechanism, can improve survival in patients with bronchogenic carcinoma.

Publication Types: Clinical Trial
Randomized Controlled Trial
PMID: 1540053 [PubMed - indexed for MEDLINE]

A preliminary report on the use of transfer factor for treating stage D3 hormone-unresponsive metastatic prostate cancer.
Biotherapy 1996;9(1-3):123-32

Pizza G, De Vinci C, Cuzzocrea D, Menniti D, Aiello E, Maver P, Corrado G, Romagnoli P, Dragoni E, LoConte G, Riolo U, Palareti A, Zucchelli P, Fornarola V, Viza D.
Immunodiagnosis and Immunotherapy Unit, S. Orsola-Malpighi Hospital, Bologna, Italy.

As conventional treatments are unsuccessful, the survival rate of stage D3 prostate cancer patients is poor. Reports have suggested the existence of humoral and cell-mediated immunity (CMI) against prostate cancer tumour-associated antigens (TAA). These observations prompted us to treat stage D3 prostate cancer patients with an in vitro produced transfer factor (TF) able to transfer, in vitro and in vivo, CMI against bladder and prostate TAA.

Fifty patients entered this study and received one intramuscular injection of 2-5 units of specific TF monthly. Follow-up, ranging from 1 to 9 years, showed that complete remission was achieved in 2 patients, partial remission in 6, and no progression of metastatic disease in 14. The median survival was 126 weeks, higher than the survival rates reported in the literature for patients of the same stage.

Publication Types:
Clinical Trial
PMID: 8993770 [PubMed - indexed for MEDLINE]

Transfer factor as an adjuvant to non-small cell lung cancer (NSCLC) therapy.
Biotherapy 1996;9(1-3):117-21

Pilotti V, Mastrorilli M, Pizza G, De Vinci C, Busutti L, Palareti A, Gozzetti G, Cavallari A.
Istituto di Clinica Chirurgica II, S. Orsola-Malpighi, Bologna, Italy.

The rationale for using transfer factor (TF) in lung cancer patients is that the possibility of improving their cell-mediated immunity to tumour associated antigens (TAA) may improve their survival.

From Jan 1984 to Jan 1995, 99 non-small cell lung cancer (NSCLC) resected patients were monthly treated with TF, extracted from the lymphocytes of blood bank donors. In the same period, 257 NSCLC resected patients were considered as non-treated controls.

The survival rates of the TF treated group appear significantly improved both for patients in stages 3a and 3b, and patients with histological subtype "large cell carcinoma" (P < 0.02). Survival of TF treated patients is also significantly higher (P < 0.02) for patients with lymph node involvement (N2 disease). The results of this study suggest that the administration of TF to NSCLC resected patients may improve survival.

Publication Types:
Clinical Trial
Controlled Clinical Trial
PMID: 8993769 [PubMed - indexed for MEDLINE]

Transfer Factor Plus&#8482;: An In Vivo Study 27 April, 2000

Purpose of Study: To determine the effectiveness of natural products in increasing the function of Natural Killer (NK) cell activity in chronic illnesses. In this study persons suffering from Fibromyalgia were chosen to take part in an in vivo study.

Background: It is felt that chronic illnesses represent immune system failures in most instances, particularly in the Fibromyalgia Syndrome. There have been many published reports of low Natural Killer cell activity or function in persons with Fibromyalgia.

Natural Killer Cells: Natural Killer cells are the first line of defense in our innate immune systems. Natural Killer cells are lethal lymphocytes containing granules filled with potent chemicals. They do not need to recognize a particular antigen but rather attack "nonself". They protect against and target tumor cells and a wide variety of infectious microbes, particularly virally infected cells. NK cells kill by binding to their targets and delivering a lethal burst of chemicals that produce holes in the target cell's membrane. Fluids seep in and leak out and the cells burst and die.

Patient Selection: Nine patients were enrolled in the study who had been diagnosed with Fibromyalgia and who weren't taking any known immune stimulants at the time of enrollment.

Nutritional Supplements Used in Study:*
Name:
Transfer Factor Plus&#8482; Dosage:
One, twice daily, days 1-10        Two, twice daily, days 11-20
Fibro AMJ&#8482; Daytime Formula Two, three times daily
Fibro AMJ&#8482; Nighttime Formula One, nightly
Choice 50&#8482; Antioxidants One, twice daily

Length of Study: Blood work was drawn on day 1 before the beginning of the use of the products and on day 21 after using the products for 20 consecutive days.

Methodology: The patients' blood was drawn and peripheral blood mononuclear cells were isolated and NK cell activity was assessed by a variation of the 51Cr release assay.

The target cells were live K562 erytholeukemic cells.
NK cytolytic activity was calculated at the baseline of day 1 and on the 21st day.
Patient NK Results
4/02/00 and 4/23/00
Name of Patient      NK Assay Baseline %      NK Assay Final %
JB: 13  and  29        DS: 13  and  19.5              CW: 13  and  31.5
PM: 6  and   25.5     LG: 9  and   25.5               SR: 10  and  25
BM: 6.5  and  27     JK: 8.5  and  23.5               MW: 11  and  35.5
Mean of Results 10  and  26.9

Comment: If a person has a Natural Killer cell activity below 20%, they are felt to be more susceptible to acute or chronic illnesses, or to have a compromised ability to recover from existing illnesses. All of the nine volunteers had NK cell function of less than 20% activity with a range of 6 to 13%, and an average of the group of 10% activity.

Summary:  All of the nine patients had significant increases in Natural Killer cell activity. The levels after 20 days on the products now ranged from 19.5% to 35.5% with an average of 26.9% or 269% of baseline.

Prior in vitro testing of Transfer Factor Plus&#8482; revealed an increase in activity of 248%. Other products were used in addition to Transfer Factor Plus&#8482; to address other issues associated with Fibromyalgia (Fibro AMJ Daytime and Nighttime Formulas and Choice 50 antioxidants).

These products are not known to have an effect on natural killer cell activity. We believe the significant immunostimulatory effect was achieved through the use of Transfer Factor Plus&#8482;.

Rob Robertson, M.D
*Products provided by 4Life&#8482; Research
2066 South 950 East, Provo, UT 84606

Transfer Factor Study with Autistic Children

9 children
ages: 2.9-9.9
average age: 5.07

These children were given three capsules of Transfer Factor, three times daily, for three months. Each patient was assessed prior to the treatment, six weeks into the study, and at the completion of the three-month study. Dr. Bock used the Gilliam Autism Rating Scale for evaluation purposes. This method applies different scores based on: stereotyped "autistic" behaviors, communication, social interaction and developmental markers. These scores are then added together to determine an autism quotient. The higher the autism quotient is, the higher the degree of autism in the patient.
At the end of the three-month study, seven out of the nine autistic children had at least some improvement.
Specifically, these improvements included:

  More attentive
  Eye contact improved
  Eczema improved
  Decreased incidence of illness
  Improved language skills
  Resolution of diarrhea
  Improved toileting skills

Although this study was small, Dr. Bock believes its results are very promising. He has included Transfer Factor as part of his treatment protocol and is excited about its possibilities for boosting the immune system in patients with autism as well as many other conditions he encounters on a daily basis.

Transfer Factor and Its Clinical Applications
  Abstract                                   by Steven J. Bock, MD
Reprinted with Permission from the International Journal of Integrative Medicine

Cancer, Cell-mediated Immunity, and Transfer Factor

Since cancer can be associated with a TH1-deficient state, use of transfer factor should be considered as part of your therapy of immune augmentation in cancer. Factors that decrease cell-mediated immunity and TH2 dominance are age, cytotoxic cancer treatments, post-surgery stress, metastatic disease, etc.(6) Cell-mediated immunity (CMI) can be a predictor of morbidity and mortality over the age of 60. In patients with liver metastases or colon rectal carcinoma, CMI is predictive of survival.(7) Decrease in cell-mediated immunity, along with an increase in circulating immune complexes, indicates unfavorable prognosis in cancer patients.(8) Studies show that patients who have multiple skin cancers had impaired CMI.(9)


In a study of gynecological cancer patients compared to control groups, those on chemotherapy had a decrease in immune perimeters (i.e., refractory decreased cell-mediated immunity), whereas the group getting immunotherapy (in this case, thymopeptin) maintained their immune perimeters at normal levels.(10,11)

Immunologically deficient cancer patients are susceptible to infection by viral pathogens, such as herpes zoster and cytomegalovirus (CMV). Infection occurs as a result of cytotoxic therapy and deficiency of cell-mediated immunity.(12) TH1-dominant states, characterized by increased amounts of IL-2 and IFN-gamma, are immuno-stimulatory and limit tumor growth. In contrast, TH2-predominant patterns, characterized by IL-4 and IL-10 cytokines, are immuno-inhibiting and stimulate tumor growth. HIV progression to HHV8 infection with Kaposi sarcoma, ulcerative colitis, progression to colon cancer, and obesity with increased incidence of carcinoma, are all associated with the increased TH2 state (and decreased cell-mediated immunity).

Studies suggest that this shift to TH2 dominance precedes the cancerous transformation. As the cancer grows, it becomes increasingly hypoxic. This leads to further suppression of cell-mediated immunity, allowing decreased immune surveillance. Studies show that a TH2 immune response is associated with a proangiogenesis state, which facilitates cancer growth.(13)

Transfer factor has been shown to improve cellular immunity in patients with immune defects.(14) Since it augments TH1 or cell-mediated immunity, transfer factor is helpful in these situations. For example, by conveying cell-mediated immunity against bladder and prostate tissue-specific antigen, transfer factor was efficacious in the treatment of stage D3 hormone-unresponsive metastatic prostate cancer. Followup showed increased survival rates in 50 patients, with complete remission in two, possible remission in six, and no progression of metastatic disease in (14,15) Transfer factor was shown to improve survival as an adjunct to resection in non-small cell lung carcinoma.(16)

Before transfer factor was derived from colostrum, it was obtained from dialyzed leukocyte extract (DLE). The literature has many citations of DLE of an antigen-specific nature being used for various viral conditions, autoimmune conditions, and certain cancers. It has been found that DLE facilitated immunity to tumor-associated antigen. Fudenburg showed that transfer factor could, from selected donors, increase the cell-mediated responses to tumor-associated antigens in human osteogenic sarcoma patients.

One of the compromises on our cell-mediated immunity is environmental stress (e.g., chemical or heavy metal pollution). It has been shown that long-term exposure to polychlorinated hydrocarbons suppresses phagocytosis, decreases NK cell activity, and reduces lymphocyte response to mitogens in mice.(17) Alterations in immune dysregulation, with a predominantly TH2 response, occurs with lead and mercury exposure. This leads to impaired cell-mediated immunity, increased incidence of infectious disease or cancer, and can end with an autoimmune disease.(18)






Transfer Factor in Allergy and ENT Patients

o Chronic sinusitis
o Chronic allergies
o Postnasal drip o Atopic diseases
o Asthma
o ENT cancer
Transfer Factor in GI Practice
o Ulcerative colitis
o Viral hepatitis
o Chronic candidiasis o Gastroenteritis
o GI cancer




Viral Infections

Currently in medicine, we are seeing increased problems with viral infections, such as otitis media, measles, chronic fatigue, Epstein-Barr virus (EBV), CMV, acquired immunodeficiency syndrome (AIDS), hepatitis, and West Nile virus. We utilize treatment regimens that range from interferon to azidothymidine (AZT), ribavirin, and relenza. However, even with all the high-tech immune weapons available, we are still losing the battle.

In the treatment of viral infections, transfer factor provides a modality that works at a fundamental level. It has been shown to induce interferon in patients with viral infections.(19)
Viral infections tend to have increased TH2 and decreased TH1. This is also seen with fungal infections, parasitic diseases, and cancer. Bacterial infections are associated with decreased TH2-dominant states.

By stimulating TH1, transfer factor may be advantageous in the treatment of hepatitis. In hepatitis C, the activation of the TH2 dominance plays a role in the development of chronic hepatitis changes. TH1 stimulation may result in clearance of viral particles and improvement in the hepatitis.(20,21) Studies show that severe complicated measles has been treated successfully with non-specific transfer factor. Symptoms were ameliorated within 24 hours, without side effects.(22)
One theory claims that one of the mechanisms involved in autistic spectrum disorders is an immune imbalance toward a dominant TH2 pattern, resulting from measles, mumps, and rubella (MMR) vaccination. Currently, a study is ongoing to test the efficacy of transfer factor to act as an immune modulator in this disorder.

It is well-known that viruses play an important role in the etiology of acute otitis media (AOM) in children. In a study of AOM, 75% of the children were positive for viruses such as respiratory syncytial virus (RSV), para influenza, and influenza, and 48% had the causal viruses in the middle ear effusion.(23) These viruses probably act as antecedents to the bacterial infections typical of AOM.(24) This could account for the excellent results seen in early treatment and prevention of otitis media using transfer factor.

A certain percentage of asthmatics have their symptoms precipitated by respiratory infection, most of these secondary to viral infections. A study conducted with transfer factor and asthmatic patients showed that approximately 50% discontinued their steroid medication and the other half decreased their steroid use. Overall, there was a decrease in hospital admissions. Administration of transfer factor improved cellular immunity. No adverse effects or allergic reactions were observed.(25)

In Annals of Allergy, Kahn reported the increased incidence of infection, such as para influenza virus, syncytial virus, adenovirus, etc., as precipitating factors in children who have asthma. It was also found that children with asthma have a propensity toward frequent infection.(26) Twelve of 15 children exhibited defects in T-cell immunity, many of which were not drastic.(27) This should emphasize that functional, suboptimal defects in cell-mediated immune function can be a factor in viral illnesses, as measured with sensitive immunological testing. Once again, we see that transfer factor can help in conditions with increased susceptibility to viruses, a dominant TH2 (decreased cell-mediated) profile.

It was found that women with extended human papilloma virus (HPV) infections have defective protective mechanisms of cell-mediated immunity.(28) A pronounced shift from TH1 to TH2 cytokine pattern is associated with more extensive HPV infection. Increased gynecological problems are found secondary to HPV. The potential of transfer factor in HPV infections needs to be further explored.





Chronic Infection
The addition of transfer factor can help an impaired immune system that is subject to chronic infections. How many practitioners see this scenario:

A child comes down with recurrent bronchitis or tonsillitis, starting shortly after birth, necessitating frequent courses of antibiotics. This can then lead to symptoms of chronic candidiasis. A history of chronic eczema or allergic diathesis can also be found. Immunological or skin testing shows a mild defect in cell-mediated immunity, but no abnormalities.

Grohn reported on several similar cases and obtained successful treatment with administration of transfer factor.(29) Here we see that transfer factor is helpful for elevated TH2 states, allergy, chronic candidiasis, and eczema.

Transfer factor has ameliorated cases of recurrent, non-bacterial cystitis (NBRC) when treatment with antibiotics and nonsteroidal drugs was unsuccessful, and cell-mediated immunity to herpes simplex and candida was decreased.(30) Various studies show positive results with transfer factor in chronic mucocutaneous candidiasis.(31)

In Lyme disease, cytotoxic production of a TH2 phenotype is correlated to resistance, while that of a TH1 phenotype is correlated to susceptibility.(32) This suggests that certain people have an immune glitch that makes their immune system prone to either the TH1 or TH2 pattern, and therefore more susceptible to different diseases. This may be precisely where transfer factor, having immune-modulating effects, can be helpful. For instance, in Lyme patients we usually see a TH1-dominated pattern, but transfer factor works very well for certain subsets of Lyme patients

Chronic Fatigue
Transfer factor has been used in chronic fatigue immune dysfunction syndrome, especially if a viral etiology can be found. It has had varied success, although one may need to use increased dosages. If polyvalent transfer factor is not successful, the use of antigen- (or disease-) specific transfer factor may need to be explored.(33)

In elderly patients with cellular immunodeficiency and chronic fatigue syndrome, age-related decrease in recovery occurred after treatment with transfer factor.34 Success with transfer factor in chronic fatigue syndrome secondary to human herpes virus 6 (HHV6), genital or labial herpes, and recurrent ocular herpes has been well-documented.35-37 A study on the effect of transfer factor on the course of multiple sclerosis showed that it retarded the progression of the disease in mild to moderate cases.(38)


The Treatment
Treatment with transfer factor is dose dependent. In viral infections, one usually starts with three capsules three times a day. The dose is then tapered down to one capsule three times a day. That dose is maintained in cases of chronic viruses, chronic herpes infection, chronic fatigue secondary to CMV or EBV, chronic colds, and impaired resistance. If there is any flare-up in viral infections, the dose can be increased to three capsules three times a day. Usually, patients report decreased susceptibility to colds, decreased nasal symptoms (for instance, postnasal drip and chronic sinus symptoms). In allergic conditions, an adult starts with two capsules three times a day, increasing to three capsules three times a day if symptoms get worse. Again, the dose is tapered to a maintenance level with amelioration of allergic symptoms.

In cases of chronic fatigue syndrome, patients start on three capsules three times a day. One may need to increase the dose depending on the response. Doses of four to five capsules three times daily can be used as an adjunct cancer treatment for patients undergoing chemotherapy and/or radiation therapy, with a resulting decrease in cellular immune function.




Transfer Factor for Immune Disorders
o Cancer
o Autoimmune states, e.g., lupus and ulcerative colitis
o Chronic fatigue
o Fibromyalgia
o Lyme disease (certain subsets)
o EBV, CMV, HHV6, and other viral infections


Various immune function tests, especially those measuring CMI, can be done to gauge maintenance dosage. One can also perform a cytokine panel, measuring IL-2, IL-4, IFN-U, IL-10, etc. An elevated IL-2 and interferon gamma would indicate a TH1-predominant state, while an elevated IL-4 and IL-10 would point to a TH2-dominated state. NK cell activity, which is usually decreased in cases of cancer, is increased secondary to transfer factor administration, and can be periodically measured.

In pediatric cases with increased susceptibility to viruses, asthma, allergic chronic sinus symptoms, and chronic candida symptoms, initial dosage is:

Under 1 Year: 1/2 capsule a day (200mg of transfer factor per capsule).
1-5 Years: 1/2 capsule a day.
6-12 Years: 1 capsule 2 times a day.
Over 12 Years 1 capsule 3 times a day

These are starting doses; the doses can be gradually increased depending on the severity of the case.
Occasionally, when a patient starts transfer factor, he or she may experience flu-like symptoms, nausea, or gastrointestinal symptoms. Since transfer factor is a small peptide and does not contain milk protein, allergic reactions are rare. These symptoms are usually classified as Jared Herxheimer mechanisms, and they probably signify a direct reaction of transfer factor on gut or systemic pathogens. If patients are informed of these possible mild adverse reactions, they are more likely to continue treatment.




Transfer Factor in Pediatric Practice
o Chronic pharyngitis
o Eczema
o Allergies
o Asthma
o Food allergies
o Autism (certain subsets)
o Prevention of vaccination-induced TH2 states
o Chronic infection
o Thrush and candidiasis
o Otitis media







Transfer Factor and Other Alternative Therapies
In complicated immune cases or in adjunct cancer treatment, it is advantageous to add complementary classes of herbs and nutrients to augment the immune-stimulatory effects. These auxiliary factors boost natural killer cell activity, increase phagocytosis, increase maturation of T-cells, enhance general immunity, and trigger the complement cascade, helping cytotoxicity. Compounds that act synergistically with transfer factor include thymic protein factors, Chinese herbs (such as astragalus, cordyceps, shiitake, maitake, and reishi), inositol hexaphosphate, melatonin, 1-3 beta glucan, glutathione, and associated antioxidants. Vitamins A, D, and B6 promote the TH2 pattern, while vitamins E, C, and folate support the production of a TH1 response.(39) Vitamin B12 suppresses the TH1 response.(40) In addition, acupuncture has been found to increase the immune perimeters of CMI. Levels of CD 3+, CD 4+, CD 4+/CD8+, and beta-endorphins were found to be increased in patients with malignant tumors after a course of acupuncture treatment.(41)

Thymic factors cause maturation of na&iuml;ve T-cells and increase cell-mediated immunity. It is known that transfer factor is more effective in post-thymic cells. Therefore, both thymic factors and transfer factors are recommended for mild thymic primary immunodeficiency.(42,43) A recent study by Dr. D. See showed that transfer factor enhanced natural killer cell cytotoxic activity. The effect of transfer factor was greater than that observed with other well-known NK cell activity enhancers, such as echinacea, acemannan, 1-3 beta glucan, IP-6, and certain Chinese mushrooms. Colostrum had 1/4 the potency. Other immune parameters, such as T-cell function and test of cellular immunity, were not done in this particular study.(44)

Conclusion
Immune system functioning is at the heart of the increasing infectious and immunologic disorders seen in clinical practices. Through its unique properties and activities, transfer factor is an extremely useful, relatively risk-free alternative and adjunctive therapy for treatment of cell-mediated or TH1-deficient conditions. Think of its potential use in illnesses such as cancer, chronic fatigue, viral infections, allergies, fungal infections, chronic infections, and autoimmune diseases.